A Study of Ad26.COV2.S in Healthy Pregnant Participants (COVID-19)

Exclusion Criteria

• •Participants with medical or obstetric histories that put them at higher risk for maternal or fetal complications (example, chronic pregnancy-related disorders, birth defects or genetic conditions during previous pregnancy)
• •Participant with abnormal pregnancy screening test (example, ultrasound fetal abnormalities, maternal blood screen)
• •Participant has a history of malignancy within 2 years before screening (exceptions are squamous, basal cell carcinomas of the skin, carcinoma in situ of the cervix, or malignancy, considered cured with minimal risk of recurrence)
• •Participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients (including specifically the excipients of the study vaccine)
• •Participant has a history of any serious, chronic, or progressive neurological disorders or seizures including Guillain-Barre syndrome, with the exception of febrile seizures during childhood
• •Participant has a positive diagnostic test result (polymerase chain reaction \[PCR\] based viral ribonucleic acid \[RNA\] detection) severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection at screening or Day 1 (if more than 4 days in between)
• •Participant has a history of thrombosis with thrombocytopenia syndrome (TTS), including cerebral venous sinus thrombosis (CVST), or heparin-induced thrombocytopenia (HIT)
• •Participant has a history of capillary leak syndrome (CLS)